Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
stocks
Ask the analyst: Can this big Covid loser scale its former heights?
Corporate Travel Management saw its profits fall through the floor during the pandemic. Our analyst Brian Han answers a reader question on what might be next.
stocks
The fight for Insignia continues
Numerous acquisition proposals vindicate Insignia's improved earnings momentum.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.40 | 31.30 | 0.36% |
| CAC 40 | 7,858.52 | 69.10 | -0.87% |
| DAX 40 | 21,125.63 | 269.30 | -1.26% |
| Dow JONES (US) | 44,424.25 | 140.82 | -0.32% |
| FTSE 100 | 8,483.58 | 18.77 | -0.22% |
| HKSE | 20,197.77 | 131.58 | 0.66% |
| NASDAQ | 19,954.30 | 99.38 | -0.50% |
| Nikkei 225 | 39,565.80 | 366.18 | -0.92% |
| NZX 50 Index | 12,999.72 | 24.98 | -0.19% |
| S&P 500 | 6,101.24 | 17.47 | -0.29% |
| S&P/ASX 200 | 8,408.90 | 30.20 | 0.36% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |